Trial · NCT03158948
Results by group319
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 319
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study Completion | Nangibotide 0.3 mg/kg/h | 12 | Participants | ||
| Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study Completion | Nangibotide 1.0 mg/kg/h | 12 | Participants | ||
| Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study Completion | Nangibotide 3.0 mg/kg/h | 11 | Participants | ||
| Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study Completion | Placebo | 10 | Participants | ||
| Systolic Blood Pressure (SBP) | Placebo | D0 | 121.5 | Full Range 87 to 149 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 0.3 mg/kg/h | D0 | 110.0 | Full Range 90 to 133 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 1.0 mg/kg/h | D0 | 121.0 | Full Range 96 to 131 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 3.0 mg/kg/h | D0 | 111.0 | Full Range 87 to 160 | mmHg |
| Systolic Blood Pressure (SBP) | Placebo | D1 | 114.5 | Full Range 82 to 131 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 0.3 mg/kg/h | D1 | 117.0 | Full Range 96 to 159 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 1.0 mg/kg/h | D1 | 112.5 | Full Range 93 to 124 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 3.0 mg/kg/h | D1 | 113.0 | Full Range 97 to 150 | mmHg |
| Systolic Blood Pressure (SBP) | Placebo | D2 | 107.0 | Full Range 104 to 110 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 0.3 mg/kg/h | D2 | 116.0 | Full Range 96 to 147 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 1.0 mg/kg/h | D2 | 121.0 | Full Range 105 to 130 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 3.0 mg/kg/h | D2 | 112.0 | Full Range 100 to 150 | mmHg |
| Systolic Blood Pressure (SBP) | Placebo | D3 | 94.0 | Full Range 87 to 101 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 0.3 mg/kg/h | D3 | 126.5 | Full Range 124 to 129 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 1.0 mg/kg/h | D3 | 108.5 | Full Range 96 to 127 | mmHg |
| Systolic Blood Pressure (SBP) | Nangibotide 3.0 mg/kg/h | D3 | 112.5 | Full Range 102 to 123 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03158948/results